KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 85 filers reported holding KALA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 7.30 and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $68,000 | -9.3% | 22,914 | +121.7% | 0.00% | – |
| Q1 2021 | $75,000 | -34.8% | 10,335 | -32.6% | 0.00% | – |
| Q4 2020 | $115,000 | +16.2% | 15,344 | +28.2% | 0.00% | – |
| Q3 2020 | $99,000 | -28.8% | 11,973 | -10.0% | 0.00% | – |
| Q2 2020 | $139,000 | +49.5% | 13,300 | +28.8% | 0.00% | – |
| Q1 2020 | $93,000 | +173.5% | 10,328 | +15.7% | 0.00% | – |
| Q4 2019 | $34,000 | +325.0% | 8,928 | +334.2% | 0.00% | – |
| Q3 2019 | $8,000 | -69.2% | 2,056 | -48.8% | 0.00% | – |
| Q2 2019 | $26,000 | +100.0% | 4,014 | +148.5% | 0.00% | – |
| Q1 2019 | $13,000 | +1200.0% | 1,615 | +624.2% | 0.00% | – |
| Q4 2018 | $1,000 | 0.0% | 223 | +182.3% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 79 | -2.5% | 0.00% | – |
| Q2 2018 | $1,000 | – | 81 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |